Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University Hospital, Brest Ministry of Health, France |
---|---|
Information provided by: | University Hospital, Brest |
ClinicalTrials.gov Identifier: | NCT00740948 |
CLINICAL PHASE II INDICATION Sjogren's syndrome RATIONALE Sjögren's syndrome (SS) is an autoimmune disorder affecting 0.2% to 3% of the general population. Pharmacological treatment can improve the sicca symptoms, often transiently, but they are unable to modify the course of the disease.Open label studies suggested that low-dose rituximab produced acute and complete CD20 depletion in blood and tissue; was well tolerated without corticosteroid use; and significantly improved glandular and extra-glandular manifestations of pSS. Larger controlled studies are now warranted. Our hypothesis is that two infusions of 1000 mg of Rituximab may be better than placebo to treat patients suffering from pSS. To test this hypothesis, we propose to compare patients with recent and/or severe pSS treated with either Rituximab or placebo.
OBJECTIVES Primary objective : Evaluation of the efficacy defined as a 30% improvement between Day 1 and Week 24 in the values on 2 of the 4 VAS measuring global scores of the disease (activity of the disease including extra glandular manifestations), joint pain, fatigue, and the most disturbing dryness.Secondary objectives : Variations from baseline to week 24 of:
The 0-100-mm VAS scores for dry mouth, dry eyes, dry trachea, dry vagina, and dry skin; fatigue; pain; Tender and swollen joint counts; Tender points; Other systemic manifestation; Unstimulated salivary flow rate; Schirmer and van Bijsterveld scores (2-3); C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR); rheumatoid factor (RF); ANA; serum IgG, IgA, and IgM; complement; cryoglobulinemia; and counts of B and T cells; Evaluation of the safety of Rituximab during the study Evaluation of the improvement evaluated on VAS by the physician Evaluation of the disease activity scores as suggested by Bowman and Vitali Evaluation of Chisholm score, B cells characteristics and DNA microarray on labial accessory salivary gland (SG) biopsy samples, and salivary gland echography at inclusion and at week 24.
TRIAL DESIGN Multicenter, randomized, double-blind, placebo-controlled trial NUMBER OF SUBJECTS : 120
Condition | Intervention | Phase |
---|---|---|
Sjogren's Disease |
Drug: Rituximab (mabthera) Injection Drug: Placebo: NaCl 0.9% or Glucose 5% |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Tolerance and Efficacy of Rituximab in Sjogren's Disease |
Estimated Enrollment: | 120 |
Study Start Date: | March 2008 |
Estimated Study Completion Date: | March 2010 |
Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Rituximab
|
Drug: Rituximab (mabthera) Injection
2 * 1g of Rituximab at the 1st day and at the 14th day.
|
2: Placebo Comparator
Placebo
|
Drug: Placebo: NaCl 0.9% or Glucose 5%
2* 250ml of NaCl 0.9% or Glucose 5% at the 1st day and at the 14th day.
|
TARGET POPULATION Inclusion criteria : Patients will be eligible if :
they fulfill the new American-European Consensus Group criteria for pSS and have :
Additional inclusion criteria will be as follows:
Exclusion criteria :
Patients should be excluded if they have a secondary SS, if they received cytotoxic drugs during the previous 4 months, if they have severe renal or haematological failure, a history of cancer, hepatitis B or C, HIV, tuberculosis, severe diabetes or any other chronic disease or evidence of infection, if they have had severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or if they are unable to understand the protocol. Other : neutrophil count < 1.5 x 103/L, live/attenuated vaccine within 28 days prior to baseline, pregnancy, breast feeding,
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
and/or at least one of the following severe signs:
Exclusion Criteria:
Contact: ALAIN SARAUX, MD, PhD | 33 2 98 34 72 67 | alain.saraux@chu-brest.fr |
France | |
CHU de Brest | Recruiting |
Brest, France, 29200 | |
Contact: Alain SARAUX, Pr 0033 2 98 34 72 70 | |
Contact: Valérie DEVAUCHELLE, Dr 0033 2 98 34 72 62 | |
Principal Investigator: Alain SARAUX, Pr | |
Sub-Investigator: Valérie DEVAUCHELLE, Dr | |
CHU Clermont-Ferrand | Recruiting |
CLERMONT-FERRAND, France, 63003 | |
Contact: Jean-Jacques DUBOST, Dr 0033 4 73 75 14 88 | |
Principal Investigator: Jean-Jacques DUBOST, Dr | |
Sub-Investigator: SOUBRIER, Dr | |
GH Le Havre | Recruiting |
Le Havre, France, 76 083 | |
Contact: Charles ZARNITSKY, Dr 0033 2 32 73 33 78 | |
Principal Investigator: Charles ZARNITSKY, Dr | |
Sub-Investigator: Didier ALCAIX, Dr | |
Sub-Investigator: Nathalie LEON, Dr | |
Ch Le Mans | Not yet recruiting |
Le Mans, France, 72 037 | |
Contact: Xavier PUECHAL, Dr 00332 43 43 26 56 | |
Principal Investigator: Xavier PUECHAL, Dr | |
Sub-Investigator: Emmanuelle DERNIS, Dr | |
CHRU de LILLE | Recruiting |
Lille, France, 59 037 | |
Contact: Eric HACHULLA, Pr 0033 3 20 44 50 48 | |
Principal Investigator: Eric HACHULLA, Pr | |
Sub-Investigator: Pierre-Yves HATRON, Pr | |
Sub-Investigator: David LAUNAY, Dr | |
Sub-Investigator: Marc LAMBERT, Dr | |
Hopital LAPEYRONIE | Recruiting |
Montpellier, France, 34 295 | |
Contact: Jacques MOREL, Dr 0033 4 67 33 86 39 | |
Principal Investigator: Jacques MOREL, Dr | |
CHU de Strasbourg | Recruiting |
Strasbourg, France, 67 200 | |
Contact: Jean SIBILIA, Pr 0033 3 88 12 71 40 | |
Principal Investigator: Jean SIBILIA, Pr | |
Sub-Investigator: Emmanuel CHATELUS, Dr | |
Sub-Investigator: Christelle SORDET, Dr | |
Hôpital Cochin APHP | Recruiting |
Paris, France, 75 679 | |
Contact: Loïc GUILLEVIN, Pr 0033 1 58 41 13 21 | |
Principal Investigator: Loïc GUILLEVIN, Pr | |
Sub-Investigator: Véronique LE GUERN, Dr | |
Sub-Investigator: Christian PAGNOUX, Dr | |
AP-HP Bicêtre | Recruiting |
Le KREMLIN-BICETRE, France, 94275 | |
Contact: Xavier MARIETTE, Pr 0033 1 45 21 37 58 | |
Principal Investigator: Xavier MARIETTE, Pr | |
Sub-Investigator: Jacques-Eric GOTTENBERG, Dr | |
Sub-Investigator: Frédéric DESMOULINS, Dr | |
Sub-Investigator: Stephan PAVY, Dr | |
Hôpital SUD CHU Rennes | Recruiting |
Rennes, France, 35 203 | |
Contact: Aleth PERDRIGER, Pr 0033 2 99 26 71 40 | |
Principal Investigator: Aleth PERDRIGER, Pr | |
CHU Rouen | Recruiting |
Rouen, France, 76 031 | |
Contact: Olivier VITTCOQ, Pr 0033 2 32 88 90 19 | |
Principal Investigator: Olivier VITTECOQ, Pr | |
Sub-Investigator: Vincent GOEB, Dr | |
Sub-Investigator: Karine LANFANT-WEYBEL, Dr | |
Sub-Investigator: Tassadit AIT ABDESSLAM, Dr | |
CHU de Nantes | Recruiting |
Nantes, France, 44 093 | |
Contact: Jean-Marie BERTHELOT, Dr 0033 2 40 08 33 41 | |
Principal Investigator: Jean-Marie BERTHELOT, Dr | |
Sub-Investigator: Mohamed HAMIDOU, Pr |
Responsible Party: | CHU Brest ( SARAUX/Principal Investigator ) |
Study ID Numbers: | TEARS |
Study First Received: | August 22, 2008 |
Last Updated: | August 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00740948 |
Health Authority: | France: Afssaps - French Health Products Safety Agency; France: French Data Protection Authority |
Sjogren's disease Rituximab Treatment anti CD20 |
Mouth Diseases Autoimmune Diseases Rituximab Joint Diseases Eye Diseases Arthritis, Rheumatoid Lacrimal Apparatus Diseases Dry Eye Syndromes |
Rheumatic Diseases Xerostomia Musculoskeletal Diseases Arthritis Connective Tissue Diseases Sjogren's Syndrome Stomatognathic Diseases Salivary Gland Diseases |
Immunologic Factors Immune System Diseases Antineoplastic Agents Therapeutic Uses |
Physiological Effects of Drugs Antirheumatic Agents Pharmacologic Actions |